Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amifurin is a photosensitizing pharmaceutical preparation derived from the seeds of the Large Bullwort (*Ammi majus*). It consists of a purified mixture of furocoumarins, primarily xanthotoxin (methoxsalen) and isopimpinellin. Amifurin is utilized in photochemotherapy (PUVA) for the treatment of dermatological conditions including vitiligo, psoriasis, and alopecia areata. Its mechanism of action involves the intercalation of the furocoumarin molecules into the double helix of DNA within epidermal cells. Upon exposure to long-wave ultraviolet radiation (UVA, 320–400 nm), these compounds undergo a photochemical reaction to form covalent mono- and bi-adducts (cross-links) with pyrimidine bases, particularly thymine. This process inhibits DNA replication and cell proliferation, while simultaneously promoting the migration and activation of melanocytes, leading to increased skin pigmentation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amifurin.